GB201911066D0 - T cell therapy - Google Patents
T cell therapyInfo
- Publication number
- GB201911066D0 GB201911066D0 GBGB1911066.7A GB201911066A GB201911066D0 GB 201911066 D0 GB201911066 D0 GB 201911066D0 GB 201911066 A GB201911066 A GB 201911066A GB 201911066 D0 GB201911066 D0 GB 201911066D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell therapy
- therapy
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1911066.7A GB201911066D0 (en) | 2019-08-02 | 2019-08-02 | T cell therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1911066.7A GB201911066D0 (en) | 2019-08-02 | 2019-08-02 | T cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201911066D0 true GB201911066D0 (en) | 2019-09-18 |
Family
ID=67809525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1911066.7A Ceased GB201911066D0 (en) | 2019-08-02 | 2019-08-02 | T cell therapy |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB201911066D0 (en) |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
WO2011140170A1 (en) | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
WO2013088114A1 (en) | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Process of expanding t cells |
US20130287748A1 (en) | 2010-12-09 | 2013-10-31 | The Trustees Of The University Of Pennsylvania | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer |
US20140120622A1 (en) | 2012-10-10 | 2014-05-01 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2015077607A1 (en) | 2013-11-22 | 2015-05-28 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human t cell receptors |
WO2015143328A1 (en) | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
WO2016191755A1 (en) | 2015-05-28 | 2016-12-01 | Adrian Bot | Diagnostic methods for t cell therapy |
WO2017049166A1 (en) | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2018002358A1 (en) | 2016-06-30 | 2018-01-04 | F. Hoffmann-La Roche Ag | Improved adoptive t-cell therapy |
WO2018081789A1 (en) | 2016-10-31 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2018081473A1 (en) | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
WO2018094167A1 (en) | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018182817A1 (en) | 2017-03-29 | 2018-10-04 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
WO2019012296A1 (en) | 2017-07-14 | 2019-01-17 | The Francis Crick Institute Limited | Analysis of hla alleles in tumours and the uses thereof |
WO2019094642A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
WO2019112932A1 (en) | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells |
-
2019
- 2019-08-02 GB GBGB1911066.7A patent/GB201911066D0/en not_active Ceased
Patent Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US9074185B2 (en) | 2009-08-28 | 2015-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
WO2011140170A1 (en) | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
US20130287748A1 (en) | 2010-12-09 | 2013-10-31 | The Trustees Of The University Of Pennsylvania | Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer |
WO2013088114A1 (en) | 2011-12-12 | 2013-06-20 | Cell Medica Limited | Process of expanding t cells |
US20140120622A1 (en) | 2012-10-10 | 2014-05-01 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
WO2015077607A1 (en) | 2013-11-22 | 2015-05-28 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human t cell receptors |
WO2015143328A1 (en) | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
WO2016191755A1 (en) | 2015-05-28 | 2016-12-01 | Adrian Bot | Diagnostic methods for t cell therapy |
WO2017049166A1 (en) | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2018002358A1 (en) | 2016-06-30 | 2018-01-04 | F. Hoffmann-La Roche Ag | Improved adoptive t-cell therapy |
WO2018081473A1 (en) | 2016-10-26 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Restimulation of cryopreserved tumor infiltrating lymphocytes |
WO2018081789A1 (en) | 2016-10-31 | 2018-05-03 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2018094167A1 (en) | 2016-11-17 | 2018-05-24 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018182817A1 (en) | 2017-03-29 | 2018-10-04 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
WO2019012296A1 (en) | 2017-07-14 | 2019-01-17 | The Francis Crick Institute Limited | Analysis of hla alleles in tumours and the uses thereof |
WO2019094642A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
WO2019100023A1 (en) | 2017-11-17 | 2019-05-23 | Iovance Biotherapeutics, Inc. | Til expansion from fine needle aspirates and small biopsies |
WO2019112932A1 (en) | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells |
Non-Patent Citations (10)
Title |
---|
ARES ET AL., COLD SPRING HARB PROTOC., vol. 2014, no. 11, 3 November 2014 (2014-11-03), pages 1139 - 48 |
BOA ET AL., CANCER INFORMATICS, vol. 13, no. 2, 2014, pages 67 - 82 |
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991 |
KAMMERMEIER ET AL., J MED GENET., vol. 51, no. 11, November 2014 (2014-11-01), pages 748 - 55 |
KOBOLDT ET AL., GENOME RES., vol. 22, 2012, pages 568 - 576 |
LANDAU ET AL., CELL, vol. 152, no. 4, 14 February 2013 (2013-02-14), pages 714 - 26 |
MARDIS, ANNU REV ANAL CHEM, 2013 |
MEYERSON ET AL., NAT. REV. GENETIC, 2010 |
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS |
YAP KL ET AL., CLIN CANCER RES., vol. 20, 2014, pages 6605 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA186123S (en) | Battery | |
SG11202101996QA (en) | Improved therapeutic t cell | |
GB201813178D0 (en) | Cell | |
EP3802802A4 (en) | Cell therapy | |
GB201803079D0 (en) | Cell | |
EP3961743A4 (en) | Battery | |
IL288221A (en) | Safe immuno-stealth cells | |
GB201900702D0 (en) | Therapy | |
CA183317S (en) | Therapy pack | |
GB201904971D0 (en) | Cell | |
CA183316S (en) | Therapy pack | |
EP4084122A4 (en) | Battery | |
GB201906202D0 (en) | Cell | |
GB201912191D0 (en) | New therapy | |
GB201807693D0 (en) | Cell | |
EP4048783C0 (en) | Modified cell | |
GB201816399D0 (en) | Cell | |
GB201805918D0 (en) | Cell | |
GB201911066D0 (en) | T cell therapy | |
IL304155A (en) | T cell therapy | |
GB202105119D0 (en) | T cell therapy | |
GB201919017D0 (en) | Cell | |
GB201918906D0 (en) | Cell | |
GB201918908D0 (en) | Cell | |
GB202006221D0 (en) | T cell therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |